Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 3/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 11/20 | 0.41 |
| ▸ | DPP4 | P27487 | 2/20 | 0.39 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.39 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | PRKG1 | Q13976 | 1/20 | 0.39 |
| ▸ | PREP | P48147 | 1/20 | 0.37 |
| ▸ | FAP | Q12884 | 1/20 | 0.37 |
| ▸ | ACACB | O00763 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26684542 | 0.91 | HRH4 (0.45) | HRH4ROCK2PRKG1ACACB | |
| SCHEMBL20756582 | 0.83 | LDHA (0.42) | ACHEHRH4ACACB | |
| SCHEMBL26684369 | 0.82 | ACHE (0.41) | ACHEHRH4PREPFAP | |
| SCHEMBL24126674 | 0.78 | CHRM1 (0.41) | ACHEHRH4ACACB | |
| SCHEMBL26684427 | 0.77 | ACACB (0.42) | ACHEHRH4ACACB | |
| SCHEMBL13034802 | 0.77 | CHKA (0.53) | ACHEDPP4DPP8DPP9DPP7 | |
| SCHEMBL15918731 | 0.77 | CHKA (0.52) | HRH4 | |
| SCHEMBL21807915 | 0.76 | HRH4 (0.59) | HRH4 | |
| SCHEMBL31051504 | 0.76 | HRH4 (0.59) | HRH4 | |
| SCHEMBL29529691 | 0.75 | HRH4 (0.54) | HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339937-A1 | CONDENSED RING COMPOUNDS THAT INHIBIT H-PGDS | SATO PHARMACEUTICAL CO., LTD. (JP) | 2023-10-26 | — | — | US | disclosed |
| US-20230339937-A1 | CONDENSED RING COMPOUNDS THAT INHIBIT H-PGDS | SATO PHARMACEUTICAL CO., LTD. (JP) | 2023-10-26 | — | — | US | disclosed |
| WO-2021256569-A1 | CONDENSED RING COMPOUNDS THAT INHIBIT H-PGDS | 佐藤製薬株式会社 | 2021-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339937-A1 | CONDENSED RING COMPOUNDS THAT INHIBIT H-PGDS | HPGDS, PTGS1, PTGIS | ACHE 3701/4885HRH4 58/4885DPP4 3593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.